Top Tech Companies in Boston, MA (4,670)

Strong Revenue Growth: Results show sustained low- to mid‑20s year‑over‑year expansion, including roughly 23% in Q2 2026 and 24% for full‑year 2025. Guidance points to continued double‑digit growth in recurring gross profit.

Profitability: Financial disclosures indicate rising GAAP profitability, with Q2 2026 net income increasing to about $154 million and adjusted EBITDA stepping up alongside raised full‑year targets. Profit growth is occurring in tandem with expanding scale across ARR, locations, and GPV.

Strong Market Position & Advantage: Evidence characterizes the company as a leading U.S. restaurant‑focused platform with approximately 180,000 locations, record quarterly net adds, and notable enterprise wins and partnerships. Scale in locations and GPV reinforces competitive positioning within restaurant technology and payments.

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Strong Revenue Growth: Recent results show accelerating top-line momentum, with FY2025 up 28% and Q2 2026 revenue up 36% year over year after 32% in Q1. Management also raised 2026 revenue guidance to $4.45B–$4.47B, indicating confidence in continued expansion.

Healthy Cash Flow: Cash generation is substantial, including Q2 2026 operating cash flow of $316M and free cash flow of $279M with about a 25% free-cash-flow margin. The company also reported roughly $5.0B in cash, cash equivalents and marketable securities as of June 30, 2026.

Customer Loyalty & Retention: Expansion within the installed base is a key driver, with about 75% of the 2025 revenue increase coming from existing customers and rising multi‑product adoption. Larger accounts are also expanding, as $100K+ ARR customers grew roughly 23% year over year to ~4,720 in Q2 2026.

Strong Revenue Growth: Revenue increased 19% in 2025 and accelerated in 2026 with 22% year-over-year growth in Q1 and 27% in Q2, while first-half 2026 revenue rose 25% year over year. Management raised full-year 2026 guidance to $94–96M, implying roughly 22–24% growth.

Customer Loyalty & Retention: Net Dollar Retention reached 117% in Q1 2026, indicating expanding spend from existing accounts after churn. Core genomics customers rose to 537 as of March 31, 2026, with record new customer additions in 2025.

Market Expansion: Geographic momentum is evident with Q1 2026 analysis volume up 28% in the U.S. and 31% in APAC, and EMEA revenue up 30%. Platform usage set records (e.g., 108,000 analyses in Q1 and 115,000 in Q2), with liquid biopsy volumes growing sharply.

Strong Revenue Growth: UK company filings indicate revenue rose from about £169.4m in 2023 to £197.0m in 2024, evidencing clear double-digit growth. Parent-company reporting in 2025 also attributed an increase in its ‘Other revenues’ to growth in Simply Business.

Profitability: Operating profit reportedly increased from roughly £24.2m to £45.9m in 2024, rising far faster than revenue. This points to improving margins and efficiency alongside scale.

Market Expansion: The business surpassed one million customers globally in 2024 and later reached one million in the UK, with continued activity in the U.S. and new partnerships and office investments. These milestones suggest ongoing expansion of reach and channels.

Investor Backing & Capital Strength: Capital resources include a $100M social bond, audited net asset growth in 2025, and $118M of impact investments deployed over four years. These signals indicate ample capacity to fund programs and expansion.

Market Expansion: Activities include the 2026 acquisition of Lab4U, scaling of Education at Work, and reported reach of 15M+ young people annually. Continued initiatives and campaigns following the 2026 rebrand point to a widening footprint.

Strategic Partnerships: Collaborations span major field builders and funders, such as the Britebound Center for Career Navigation at JFF and a grantee community of 100+ organizations across 49 states and Puerto Rico. These ties support national presence and program scaling.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Investor Backing & Capital Strength: Multiple funding rounds, including $8.2M in 2020, a $20M Series A in 2021 at a reported $100M valuation, and a $17M investment in 2026 from Enlightened Hospitality Investments, indicate strong capital support. The 2026 round is tied to product/engineering investment and go-to-market expansion.

Market Expansion: Customer reach spans hospitality, retail, transportation, healthcare, manufacturing, and logistics, with deployments cited across 32 countries and large-scale rollouts at brands such as McDonald’s and Elara Caring. A 2026 global partnership with Shake Shack and the addition of 700,000+ hospitality users in 2025 underscore geographic and vertical growth.

Strong Revenue Growth: ARR reportedly increased from $200K (Apr 2019) to $5M (Feb 2023), and U.S. growth of 159% was reported for fiscal 2023. These signals point to substantial revenue momentum even though more recent ARR figures are not disclosed.

Investor Backing & Capital Strength: Funding progressed from a 2022 seed to a 2023 Series A and a $27M Series B in 2025, led by established firms, indicating strong capital support. Independent listings also note roughly $44M+ raised to date.

Market Expansion: The customer base expanded from 1,000+ paying businesses in 2022 to 6,000+ across all 50 states by 2025–2026, signaling broader penetration. Reported booked business rose from $25M+ (2022) to $655M+ (2025) and $1.2B+ (2026), reflecting sharply higher platform activity.

Product Line Growth: Offerings evolved from AI-generated websites to a broader suite spanning marketing, bookings, payments, CRM/messaging, and an AI 'Sidekick' mobile app. This widening scope is accompanied by continued hiring across sales, product, engineering, and AI/ML to support scale.

Strong Market Position & Advantage: Adoption spans 1,300+ biotechnology organizations with usage reported across more than half of the top 50 biopharma companies, signaling durable positioning in life‑sciences R&D software. Multiple sources characterize the platform as a leading life‑sciences R&D cloud used by both startups and major enterprises.

Product Line Growth: The company continues to launch and expand major offerings, including Benchling AI, antibody‑discovery capabilities, automation/analysis tools, and extensions into new scientific workflows such as small‑molecule chemistry. Acquisitions like PipeBio further broaden capability depth in biologics and related R&D domains.

Innovation-Driven Growth: AI is a clear growth vector, with reports that 500 biotech companies used Benchling AI in its first year and the product subsequently reached general availability. Team acquisitions (e.g., ReSync Bio and Sphinx Bio) and partnerships (e.g., with Anthropic) underscore a deliberate push to embed advanced models into scientific workflows.

Strong Hiring & Retention: Headcount is described as rising from about 134 in 2023 to roughly 176 by March 2026, and job postings increased from 2024 into 2026, pointing to active hiring. This trend indicates added capacity to support continued expansion.

Strategic Partnerships: A global partnership model announced in 2024 brought other freelance marketplaces into the network, signaling deliberate ecosystem expansion. These partnerships support broader geographic reach and customer access.

Strong Market Position & Advantage: The company highlights a substantial enterprise footprint, including a significant share of Fortune 500 companies, reflecting deep penetration at the high end of the market. It was also named the 2nd fastest‑growing company in Massachusetts based on three‑year revenue growth, reinforcing competitive standing.

Product Line Growth: Product offerings have expanded from consumer robots (gita, gitamini) to the B2B kilo platform, with additional features like Forward Following, Trips, and hybrid navigation introduced in 2025–2026. This points to an actively developing portfolio rather than a static lineup.

Market Expansion: The move from consumer-focused products into manufacturing, warehousing, and facilities management signals a broader addressable market. Parent-company materials in 2026 still describe active marketing and Boston-based manufacturing across multiple robot platforms.

Innovation-Driven Growth: Continued releases such as a production-ready hybrid-navigation AI model and other capability updates indicate ongoing R&D and technology maturation. Brand collaborations like the Grogu/Star Wars gitamini also reflect sustained commercialization activity.

Profitability: Net income rose to $6.79B in 2025 from $4.38B in 2024. The combined ratio improved materially (e.g., S&P-adjusted 89.7% in 2025 and high-80s in early 2026), indicating stronger underwriting performance.

Investor Backing & Capital Strength: Shareholders’ equity increased from about $22.2B in 2022 to $39.9B at year-end 2025 and exceeded $44B by mid-2026. External ratings actions (AM Best A affirmation in Sept 2025; S&P upgrade to A+ in July 2026) underscore improved capitalization.

Resilient & Sustainable Growth: S&P describes deliberate portfolio reshaping and expects 2–3% annual premium growth during 2026–2028. Management emphasizes disciplined, selective expansion following underwriting improvements, prioritizing durable returns over sheer volume.

Strong Market Position & Advantage: Gartner included Robin as a Leader in its 2026 Magic Quadrant for Workplace Experience Applications, indicating strong competitive standing in this category. The company’s statement that it serves thousands of organizations further reflects broad market presence.

Market Expansion: The July 2026 launch on Google Cloud Marketplace opens a new procurement path through existing Google Cloud commitments for enterprise buyers. This move represents a meaningful extension of distribution and market access.

Product Line Growth: The platform has expanded from room/desk booking into a broader workplace-operations suite covering visitor management, space planning, analytics, and AI. 2026 updates such as a natural-language workplace agent, CAD-to-map functionality, and move-management tools illustrate continued breadth.

Strong Revenue Growth: Available evidence indicates sustained top-line expansion, with company-reported growth corroborated by repeated placements on independent fast-growth lists such as the Inc. 5000 and the Financial Times’ Americas ranking. These signals collectively point to continuing revenue momentum rather than a one-off spike.

Strong Hiring & Retention: Headcount has increased substantially since 2021, with recent statements describing ongoing hiring and acceleration year over year. Active postings across Cloud Engineering, ServiceNow, and related roles further indicate expansion of the workforce.

Market Expansion: The company extended its footprint beyond North America into EMEA and later into APAC, including initial hires in Australia. Growth in delivery activity and practice presence across these regions suggests a broader market reach.

Investor Backing & Capital Strength: Fresh equity and repeat securitizations are expanding financing capacity, including a $50M raise in December 2025 and multiple HEI securitizations culminating in a $300M deal in 2025. These transactions provide recycled capital to originate more home equity investments.

Strong Market Position & Advantage: Independent and company disclosures place Hometap among a small cohort leading HEIs, with more than $2B deployed and 20,000–24,000+ homeowners served. Prominent coverage and regulatory overviews consistently cite the firm alongside top peers in this niche.

Market Expansion: Geographic reach and customer count advanced through 2025–2026, with offerings rolled out to additional states and homeowners served progressing from 20,000+ to 24,000+. Company outlook materials frame 2026 as a period of “disciplined expansion,” aligning with continued footprint growth.

Strong Revenue Growth: Recent results show revenue rising from $1.62B in FY2023 to $2.17B in FY2024, $2.67B in FY2025, and about $3.35B in FY2026, with Q4 FY2026 up 25% year over year. This trajectory, alongside mid‑20% ARR growth, indicates continued expansion rather than a stall.

Healthy Cash Flow: Cash generation is growing, with free cash flow rising to about $779M in FY2026 and a free‑cash‑flow margin near 23%. Non‑GAAP operating metrics, including an ~80% gross margin, underscore operating leverage.

Strong Market Position & Advantage: Industry evaluations list the company as a Leader in the 2026 Gartner Magic Quadrants for both SSE and SASE, with five consecutive years of SSE leadership. Expanding large‑enterprise adoption and thousands of customers support a durable position in its core zero trust/SSE markets.

Market Expansion: District reach has expanded from 1,000+ around the 2021 acquisition to 1,900+ by early 2026, with coverage across 50+ states and over half of U.S. EL students. This indicates broadening geographic penetration and customer footprint.

Product Line Growth: The offering has evolved from EL program management and instructional tools into a unified ELD platform that now includes benchmark assessment via the 2026 Ellevation Benchmark launch. This broader scope points to increased relevance and potential expansion within existing districts.

Strong Market Position & Advantage: The company is frequently described as a leading, specialized provider in its EL/MLL niche, serving 1,900+ districts and 2.5M+ learners. Such penetration suggests a defensible position within its targeted category.

Strong Revenue Growth: Revenue is reported to have expanded dramatically over a recent three-year period, earning recognition on a leading high-growth list. Feedback suggests this reflects substantial commercial traction rather than growth based solely on financing.

Strong Market Position & Advantage: Customer adoption spans 500+ MedTech companies, including deep penetration among the largest enterprises (e.g., 16 of the top 20). Feedback suggests this breadth and upmarket presence signal durable positioning within its niche.

Investor Backing & Capital Strength: Capital raised has surpassed $160M with a recent late-stage round and a valuation near the unicorn threshold. Feedback suggests this funding base supports continued product expansion, AI initiatives, and go-to-market scale.

Market Expansion: ASI has broadened beyond commercial aviation into defense and critical infrastructure, adding a DIU sustainment tool, a National Grid collaboration, and a Joby partnership alongside a major FAA program rolling out from the Washington, D.C. region. Company materials describe a scope spanning aviation, defense, logistics, energy and more, with locations in Boston, Washington, D.C., and Gdańsk.

Strong Market Position & Advantage: A 12-year, $875M FAA selection for FMDS and SMART—now in operational deployment around Washington, D.C.—signals meaningful competitive strength at national scale. Available reporting indicates ASI prevailed in a field that included larger incumbents, underscoring differentiation.

Strong Hiring & Retention: Signals include a “rapidly expanding team,” added offices, and recent defense-oriented roles (e.g., a Data Lead in Colorado Springs), with external coverage citing 165+ employees and plans to grow beyond 250 to deliver major programs. Active postings across technical and federal roles further reflect continued team build-out.